How do you treat patients with newly diagnosed CLL in the era of new agents? In this commentary, Dr. Flinn discusses emerging frontline combination regimens for the treatment of CLL.
Are you aware of some of the latest clinical data in CLL? In this commentary, I will discuss 3 key studies on venetoclax, acalabrutinib, and lisocabtagene maraleucel in CLL that were presented at ASCO 2019.
Farrukh Awan, MD, MS, discusses recent advances and clinical data in CLL that led to an updated online treatment decision support tool for CLL from Clinical Care Options.
Acalabrutinib is now approved for treating patients with CLL. Are you ready to incorporate it into your practice?
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.